Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria K Angelopoulou

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Seminars in Hematology|March 20, 2013
Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 yearsTheodoros P Vassilakopoulos, Maria K Angelopoulou
Seminars in Hematology|August 7, 2016
Prognostic factors in Hodgkin lymphomaPaul J Bröckelmann, Maria K Angelopoulou, Theodoros P Vassilakopoulos
Leukemia Research|August 7, 2009
Incorporating novel agents in the treatment of myelodysplastic syndromesKonstantinos Anargyrou, Theodoros P Vassilakopoulos, Maria K Angelopoulou, et al.
Therapeutic Advances in Hematology|February 29, 2020
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategiesTheodoros P Vassilakopoulos, John V Asimakopoulos, Kostas Konstantopoulos, et al.
Best Practice & Research. Clinical Haematology|March 15, 2017
Treatment of splenic marginal zone lymphomaChristina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Biomed Research International|September 9, 2014
New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patientsMaria K Angelopoulou, Pantelis Tsirkinidis, Georgios Boutsikas, et al.
Journal of Clinical Medicine|February 26, 2025
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell LymphomaAthanasios Liaskas, Maria N Dimopoulou, Alexia Piperidou, et al.
Best Practice & Research. Clinical Haematology|February 18, 2018
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?Christina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Leukemia & Lymphoma|September 21, 2013
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Christina Kalpadakis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, et al.
International Journal of Molecular Sciences|September 9, 2023
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin LymphomaTheodoros P Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Seminars in Hematology|March 20, 2013
Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 yearsTheodoros P Vassilakopoulos, Maria K Angelopoulou
Seminars in Hematology|August 7, 2016
Prognostic factors in Hodgkin lymphomaPaul J Bröckelmann, Maria K Angelopoulou, Theodoros P Vassilakopoulos
Leukemia Research|August 7, 2009
Incorporating novel agents in the treatment of myelodysplastic syndromesKonstantinos Anargyrou, Theodoros P Vassilakopoulos, Maria K Angelopoulou, et al.
Therapeutic Advances in Hematology|February 29, 2020
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategiesTheodoros P Vassilakopoulos, John V Asimakopoulos, Kostas Konstantopoulos, et al.
Best Practice & Research. Clinical Haematology|March 15, 2017
Treatment of splenic marginal zone lymphomaChristina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Biomed Research International|September 9, 2014
New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patientsMaria K Angelopoulou, Pantelis Tsirkinidis, Georgios Boutsikas, et al.
Journal of Clinical Medicine|February 26, 2025
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell LymphomaAthanasios Liaskas, Maria N Dimopoulou, Alexia Piperidou, et al.
Best Practice & Research. Clinical Haematology|February 18, 2018
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?Christina Kalpadakis, Gerassimos A Pangalis, Maria K Angelopoulou, et al.
Leukemia & Lymphoma|September 21, 2013
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Christina Kalpadakis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, et al.
International Journal of Molecular Sciences|September 9, 2023
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin LymphomaTheodoros P Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, et al.
Pageof 10